{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:09:40Z","timestamp":1788174580503,"version":"build-2803163510"},"reference-count":53,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Patients with chronic lymphocytic leukemia (CLL) treated with B-cell pathway inhibitors and anti-CD20 antibodies exhibit low humoral response rates following SARS-CoV-2 vaccination. To investigate this observation, a prospective single-institution study was conducted comparing peripheral blood mononuclear cell transcriptional response with antibody and T-cell response rates following heterologous BNT162b2\/ChAdOx1 vaccination of 15 patients with CLL\/small lymphocytic lymphoma (SLL). Two-dose antibody response rate was 40%, increasing to 53% after booster. Patients on Bruton tyrosine kinase inhibitor (BTKi) and venetoclax\u00a0\u00b1 anti-CD20 antibody within 12\u00a0months of vaccination responded inferiorly compared with those under BTKi alone. The 2-dose\u2013T-cell response rate was 80%, which increased to 93% after the booster dose. Key transcriptional findings were that interferon\u2013mediated signaling activation including activation of the JAK-STAT pathway generally occurred within days of vaccination, but was independent from the magnitude of the antibody response. Increasing counts of IGHV genes were associated with B-cell reconstitution and improved humoral response rate in the vaccinated patients. T-cell responses in patients with CLL appeared independent of treatment status, whereas higher humoral response rate was associated with BTKi treatment and B-cell reconstitution. Boosting was particularly effective when intrinsic immune status was improved by CLL treatment. Limitations included studying a relatively small cohort, with different treatments and vaccination schedules.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008445","type":"journal-article","created":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T19:19:53Z","timestamp":1673464793000},"page":"2214-2227","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":13,"title":["Analysis of immune responses in patients with CLL after heterologous COVID-19 vaccination"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7785-5942","authenticated-orcid":false,"given":"Hye Kyung","family":"Lee","sequence":"first","affiliation":[{"name":"1National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3526-9523","authenticated-orcid":false,"given":"Manuela A.","family":"Hoechstetter","sequence":"additional","affiliation":[{"name":"2Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4196-096X","authenticated-orcid":false,"given":"Maike","family":"Buchner","sequence":"additional","affiliation":[{"name":"3Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany"},{"name":"4TranslaTUM-Central Institute for Translational Cancer Research, Technische Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trang Thu","family":"Pham","sequence":"additional","affiliation":[{"name":"2Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3449-0461","authenticated-orcid":false,"given":"Jin Won","family":"Huh","sequence":"additional","affiliation":[{"name":"5Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2890-7515","authenticated-orcid":false,"given":"Katharina","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"6Bundeswehr Institute of Microbiology, Munich, Germany"},{"name":"7German Centre for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8721-9248","authenticated-orcid":false,"given":"Sabine","family":"Zange","sequence":"additional","affiliation":[{"name":"6Bundeswehr Institute of Microbiology, Munich, Germany"},{"name":"7German Centre for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4373-0823","authenticated-orcid":false,"given":"Heiner","family":"von Buttlar","sequence":"additional","affiliation":[{"name":"6Bundeswehr Institute of Microbiology, Munich, Germany"},{"name":"7German Centre for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1370-4114","authenticated-orcid":false,"given":"Philipp","family":"Girl","sequence":"additional","affiliation":[{"name":"6Bundeswehr Institute of Microbiology, Munich, Germany"},{"name":"7German Centre for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8756-7821","authenticated-orcid":false,"given":"Roman","family":"W\u00f6lfel","sequence":"additional","affiliation":[{"name":"6Bundeswehr Institute of Microbiology, Munich, Germany"},{"name":"7German Centre for Infection Research, Partner Site Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4212-0791","authenticated-orcid":false,"given":"Lisa","family":"Brandmeier","sequence":"additional","affiliation":[{"name":"3Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Pfeuffer","sequence":"additional","affiliation":[{"name":"3Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3883-0715","authenticated-orcid":false,"given":"Priscilla A.","family":"Furth","sequence":"additional","affiliation":[{"name":"8Departments of Oncology & Medicine, Georgetown University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2866-2260","authenticated-orcid":false,"given":"Clemens-Martin","family":"Wendtner","sequence":"additional","affiliation":[{"name":"2Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilian University, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8319-9841","authenticated-orcid":false,"given":"Lothar","family":"Hennighausen","sequence":"additional","affiliation":[{"name":"1National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"issue":"10","key":"2023052315241295400_bib1","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"issue":"9","key":"2023052315241295400_bib2","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarfo","year":"2020","journal-title":"Leukemia"},{"issue":"18","key":"2023052315241295400_bib3","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1182\/blood.2021011841","article-title":"COVID-19 in patients with CLL: improved survival outcomes and update on management strategies","volume":"138","author":"Roeker","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2023052315241295400_bib4","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in chronic lymphocytic leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"2023052315241295400_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10428194.2012.706285","article-title":"Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia","volume":"54","author":"Freeman","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023052315241295400_bib6","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2015-03-567388","article-title":"Perturbation of the normal immune system in patients with CLL","volume":"126","author":"Forconi","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2023052315241295400_bib7","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3324\/haematol.2021.279196","article-title":"Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"107","author":"Benjamini","year":"2022","journal-title":"Haematologica"},{"issue":"2","key":"2023052315241295400_bib8","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ejh.13722","article-title":"Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia","volume":"108","author":"Morawska","year":"2022","journal-title":"Eur J Haematol"},{"issue":"9","key":"2023052315241295400_bib9","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1038\/s41375-021-01270-w","article-title":"COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia","volume":"35","author":"Roeker","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"2023052315241295400_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1182\/blood.2021013445","article-title":"Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients","volume":"139","author":"Liebers","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023052315241295400_bib11","doi-asserted-by":"crossref","first-page":"ofab353","DOI":"10.1093\/ofid\/ofab353","article-title":"Suboptimal response to coronavirus disease 2019 messenger RNA vaccines in patients with hematologic malignancies: a need for vigilance in the postmasking era","volume":"8","author":"Agha","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"2023052315241295400_bib12","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2021.06.008","article-title":"Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer","volume":"154","author":"Barriere","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"2023052315241295400_bib13","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1002\/ajh.26284","article-title":"BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies","volume":"96","author":"Herzog Tzarfati","year":"2021","journal-title":"Am J Hematol"},{"issue":"5","key":"2023052315241295400_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1182\/blood.2021014085","article-title":"Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination","volume":"139","author":"Herishanu","year":"2022","journal-title":"Blood"},{"issue":"7","key":"2023052315241295400_bib15","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-021-00528-x","article-title":"Antibody responses after first and second Covid-19 vaccination in patients with chronic lymphocytic leukaemia","volume":"11","author":"Parry","year":"2021","journal-title":"Blood Cancer J"},{"key":"2023052315241295400_bib16","doi-asserted-by":"crossref","first-page":"104073","DOI":"10.1016\/j.ebiom.2022.104073","article-title":"Heterologous ChAdOx1\/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: the pragmatic, multi-center, three-arm, partially randomized HEVACC trial","volume":"80","author":"Banki","year":"2022","journal-title":"EBioMedicine"},{"issue":"6","key":"2023052315241295400_bib17","doi-asserted-by":"crossref","first-page":"104473","DOI":"10.1016\/j.isci.2022.104473","article-title":"Heterologous ChAdOx1-BNT162b2 vaccination in Korean cohort induces robust immune and antibody responses that includes Omicron","volume":"25","author":"Lee","year":"2022","journal-title":"iScience"},{"key":"2023052315241295400_bib18","unstructured":"European Medicines Agency. https:\/\/www.ema.europa.eu\/en\/news\/ema-ecdc-recommendations-heterologous-vaccination-courses-against-covid-19-mix-match-approach-can-be."},{"issue":"6","key":"2023052315241295400_bib19","doi-asserted-by":"crossref","first-page":"e202201381","DOI":"10.26508\/lsa.202201381","article-title":"mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients","volume":"5","author":"Azzolini","year":"2022","journal-title":"Life Sci Alliance"},{"issue":"4","key":"2023052315241295400_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ijc.34209","article-title":"Response to anti-SARS-CoV-2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients","volume":"152","author":"Zaleska","year":"2022","journal-title":"Int J Cancer"},{"key":"2023052315241295400_bib21","first-page":"6831640","article-title":"Immunogenicity of Pfizer mRNA COVID-19 vaccination followed by J&J adenovirus COVID-19 vaccination in two patients with chronic lymphocytic leukemia","author":"Lyski","year":"2022","journal-title":"Case Rep Hematol"},{"issue":"6","key":"2023052315241295400_bib22","doi-asserted-by":"crossref","first-page":"108728","DOI":"10.1016\/j.celrep.2021.108728","article-title":"Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients","volume":"34","author":"Tan","year":"2021","journal-title":"Cell Rep"},{"issue":"3","key":"2023052315241295400_bib23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/bjh.17877","article-title":"T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies","volume":"196","author":"Marasco","year":"2022","journal-title":"Br J Haematol"},{"issue":"5","key":"2023052315241295400_bib24","doi-asserted-by":"crossref","first-page":"e20202617","DOI":"10.1084\/jem.20202617","article-title":"Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection","volume":"218","author":"Le Bert","year":"2021","journal-title":"J Exp Med"},{"issue":"2","key":"2023052315241295400_bib25","doi-asserted-by":"crossref","first-page":"110680","DOI":"10.1016\/j.celrep.2022.110680","article-title":"mRNA vaccination in octogenarians 15 and 20\u00a0months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron","volume":"39","author":"Lee","year":"2022","journal-title":"Cell Rep"},{"issue":"4","key":"2023052315241295400_bib26","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3390\/idr14040057","article-title":"Mix-and-match COVID-19 vaccinations (heterologous boost): a review","volume":"14","author":"Garg","year":"2022","journal-title":"Infect Dis Rep"},{"key":"2023052315241295400_bib27","doi-asserted-by":"crossref","first-page":"101642","DOI":"10.1016\/j.eclinm.2022.101642","article-title":"Immune responses following 3rd and 4th doses of heterologous and homologous COVID-19 vaccines in kidney transplant recipients","volume":"53","author":"Thomson","year":"2022","journal-title":"EClinicalMedicine"},{"key":"2023052315241295400_bib28","unstructured":"Epidemiologisches Bulletin 39\/2021. Accessed  June 2021. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2021\/Ausgaben\/39_21.html."},{"issue":"4","key":"2023052315241295400_bib29","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1007\/s40121-021-00521-8","article-title":"Preliminary evaluation of QuantiFERON SARS-CoV-2 and QIAreach anti-SARS-CoV-2 total test in recently vaccinated individuals","volume":"10","author":"Jaganathan","year":"2021","journal-title":"Infect Dis Ther"},{"key":"2023052315241295400_bib30","doi-asserted-by":"crossref","first-page":"104912","DOI":"10.1016\/j.jcv.2021.104912","article-title":"Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2","volume":"142","author":"Muller","year":"2021","journal-title":"J\u00a0Clin Virol"},{"issue":"15","key":"2023052315241295400_bib31","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/bioinformatics\/btu170","article-title":"Trimmomatic: a flexible trimmer for Illumina sequence data","volume":"30","author":"Bolger","year":"2014","journal-title":"Bioinformatics"},{"issue":"1","key":"2023052315241295400_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"issue":"2","key":"2023052315241295400_bib33","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","article-title":"HTSeq--a Python framework to work with high-throughput sequencing data","volume":"31","author":"Anders","year":"2015","journal-title":"Bioinformatics"},{"issue":"12","key":"2023052315241295400_bib34","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"issue":"9","key":"2023052315241295400_bib35","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nbt.2931","article-title":"Normalization of RNA-seq data using factor analysis of control genes or samples","volume":"32","author":"Risso","year":"2014","journal-title":"Nat Biotechnol"},{"key":"2023052315241295400_bib36","author":"Wickham","year":"2009"},{"issue":"5","key":"2023052315241295400_bib37","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nmeth.3364","article-title":"MiXCR: software for comprehensive adaptive immunity profiling","volume":"12","author":"Bolotin","year":"2015","journal-title":"Nat Methods"},{"issue":"10","key":"2023052315241295400_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nbt.3979","article-title":"Antigen receptor repertoire profiling from RNA-seq data","volume":"35","author":"Bolotin","year":"2017","journal-title":"Nat Biotechnol"},{"key":"2023052315241295400_bib39","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221090150","article-title":"Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study","volume":"13","author":"Diamantopoulos","year":"2022","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"2023052315241295400_bib40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.humimm.2021.10.007","article-title":"Landscapes and dynamic diversifications of B-cell receptor repertoires in COVID-19 patients","volume":"83","author":"Xiang","year":"2022","journal-title":"Hum Immunol"},{"issue":"7889","key":"2023052315241295400_bib41","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/s41586-021-04117-7","article-title":"Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants","volume":"600","author":"Andreano","year":"2021","journal-title":"Nature"},{"key":"2023052315241295400_bib42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-020-0168-9","article-title":"Immune cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing","volume":"6","author":"Wen","year":"2020","journal-title":"Cell Discov"},{"issue":"1","key":"2023052315241295400_bib43","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41392-021-00610-7","article-title":"Rapid isolation and immune profiling of SARS-CoV-2 specific memory B cell in convalescent COVID-19 patients via LIBRA-seq","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"9","key":"2023052315241295400_bib44","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/s41590-020-0762-x","article-title":"Single-cell landscape of immunological responses in patients with COVID-19","volume":"21","author":"Zhang","year":"2020","journal-title":"Nat Immunol"},{"issue":"1","key":"2023052315241295400_bib45","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41421-021-00321-x","article-title":"Dynamics of TCR repertoire and T cell function in COVID-19 convalescent individuals","volume":"7","author":"Luo","year":"2021","journal-title":"Cell Discov"},{"issue":"1","key":"2023052315241295400_bib46","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41392-021-00526-2","article-title":"Dynamic blood single-cell immune responses in patients with COVID-19","volume":"6","author":"Huang","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"2023052315241295400_bib47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s43856-022-00083-x","article-title":"BNT162b2 vaccination enhances interferon-JAK-STAT-regulated antiviral programs in COVID-19 patients infected with the SARS-CoV-2 beta variant","volume":"2","author":"Knabl","year":"2022","journal-title":"Commun Med (Lond)"},{"issue":"4","key":"2023052315241295400_bib48","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/bloodadvances.2021006633","article-title":"Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia","volume":"6","author":"Lyski","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2023052315241295400_bib49","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/s41467-022-28578-0","article-title":"Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies","volume":"13","author":"Re","year":"2022","journal-title":"Nat Commun"},{"issue":"6","key":"2023052315241295400_bib50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/bjh.18149","article-title":"Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination","volume":"197","author":"Riise","year":"2022","journal-title":"Br J Haematol"},{"issue":"4","key":"2023052315241295400_bib51","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3324\/haematol.2021.280300","article-title":"T-cell immune responses following vaccination with mRNA BNT162b2 against SARS-CoV-2 in patients with chronic lymphocytic leukemia: results from a prospective open-label clinical trial","volume":"107","author":"Blixt","year":"2022","journal-title":"Haematologica"},{"issue":"23","key":"2023052315241295400_bib52","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"2023052315241295400_bib53","doi-asserted-by":"crossref","first-page":"686768","DOI":"10.3389\/fimmu.2021.686768","article-title":"BTK inhibitors in chronic lymphocytic leukemia: biological activity and immune effects","volume":"12","author":"Palma","year":"2021","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2214\/2052311\/blooda_adv-2022-008445-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/10\/2214\/2052311\/blooda_adv-2022-008445-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T15:39:56Z","timestamp":1684856396000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/10\/2214\/494070\/Analysis-of-immune-responses-in-patients-with-CLL"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":53,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,5,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008445","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}